N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: Results from 15-year follow-up of WOSCOPS

European Heart Journal

Volumn 34, Issue 6, 2013, Pages 443-450

  Welsh, Paul ^a,b   Doolin, Orla ^a   Willeit, Peter ^c   Packard, Chris ^a   MacFarlane, Peter ^a   Cobbe, Stuart ^a   Gudnason, Vilmundur ^d,e   Di Angelantonio, Emanuele ^c   Ford, Ian ^a   Sattar, Naveed ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF ICELAND   (Iceland)

^e ICELANDIC HEART ASSOCIATION   (Iceland)

Author keywords

Epidemiology; Natriuretic peptides; NT proBNP; Risk factors

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FOLLOW UP; HEART INDEX; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; TREATMENT DURATION;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; ELECTROCARDIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SCOTLAND;

EID: 84873653206     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs239     Document Type: Article

References (30)

1. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009;120:2177-2187.
2. Rana BS, Davies JI, Band MM, Pringle SD, Morris A, Struthers AD. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes. Heart 2006;92:916-920.
3. Wong KY, McSwiggan S, Kennedy NS, MacWalter RS, Struthers AD. B-type natriuretic peptide identifies silent myocardial ischaemia in stroke survivors. Heart 2006;92:487-489.
4. Noman A, George J, Struthers A. A new use for B-type natriuretic peptide: to detect myocardial ischaemia in non-heart failure patients. Br J Diabetes Vasc Dis 2010;10:78-82.
5. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-2116.
6. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S,Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007;28:1374-1381.
7. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tunstall-Pedoe H, Kuulasmaa K, Yarnell J, Schnabel RB, Wild PS, Munzel TF, Lackner KJ, Tiret L, Evans A, Salomaa V. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010;121: 2388-2397.
8. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302: 49-57.
9. Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, Breteler MM, Witteman JC, van den Meiracker AH. Aminoterminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension 2010; 55:785-791.
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
11. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-1155.
12. Ford I for The WOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. West of Scotland Coronary Prevention Study. Am J Cardiol 1995;76:485-491.
13. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of theWest of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-1486.
14. Ford I, Shepherd J, Cobbe SM, Lorimer AR, McKillop J, Packard C, Macfarlane P, Isles C. A coronary primary prevention study of Scottish men aged 45-64 years: trial design. J Clin Epidemiol 1992;45:849-860.
15. Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen, UK: Aberdeen University Press; 1991.
16. Macfarlane PW, Devine B, Latif S, McLaughlin S, Shoat DB, Watts MP. Methodology of ECG interpretation in the Glasgow program. Methods Inf Med 1990; 29:354-361.
17. Macfarlane PW, Latif S. Automated serial ECG comparison based on the Minnesota code. J Electrocardiol 1996;29(Suppl):29-34.
18. Sigurdsson E, Sigfusson N, Sigvaldason H, Thorgeirsson G. Silent ST-T changes in an epidemiologic cohort study-a marker of hypertension or coronary heart disease, or both: the Reykjavik study. J Am Coll Cardiol 1996;27: 1140-1147.
19. Shepherd J, Cobbe SM, Lorimer AR, McKillop J, Ford I, Packard C, Macfarlane P, Isles C, Oliver M, Lever AF, Brown BW, Ledingham JGG, Pocock S, Rifkind B, Vallance B, Ballantyre D, Duncan D, Anderson L, Montgomery V, for the West of Scotland Coronary Prevention Study Group. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. J Clin Epidemiol 1995;48: 1441-1452.
20. Preiss D, Welsh P, Murray HM, Shepherd J, Packard C, Macfarlane P, Cobbe S, Ford I, Sattar N. Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. Eur Heart J 2010;31:1230-1236.
21. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistributionof a competing risk. J Am Stat Assoc 1999;94:496-509.
23. Therneau TM, Grambsch PM. Modelling Survival Data: Extending the Cox Model. New York: Springer; 2000.
24. Sattar N, Murray HM, Welsh P, Blauw GJ, Buckley BM, Cobbe S, de Craen AJ, Lowe GD, Jukema JW, Macfarlane PW, Murphy MB, Stott DJ, Westendorp RG, Shepherd J, Ford I, Packard CJ.; Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 2009; 6:e1000099.
25. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
26. Wolbers M, Koller MT, Witteman JCM, Steyerberg EW. Prognostic Models With Competing Risks-Methods and Application to Coronary Risk Prediction. Epidemiology 2009;20:555-561.
27. Tunstall-Pedoe H, Woodward M, Tavendale R, A'Brook R, McCluskey MK. Comparison of the prediction by 27 different factors of coronary heart disease and death in men and women of the Scottish Heart Health Study: cohort study. BMJ 1997;315:722-729.
28. Wannamethee G,Welsh P, Lowe GD, Gudnason V, Di Angelantonio E, Lennon L, Rumley A, Whincup PH, Sattar N. N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without preexisting cardiovascular disease. JACC 2011;58: 56-64.
29. Welsh P, Packard CJ, Sattar N. Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar. Curr Opin Lipidol 2008;19:563-571.
30. Cauliez B, Guignery J, Marinier S, Mariau I, Lavoinne A. Two-year stability of NT-proBNP in frozen samples using the Roche Elecsys system. Ann Clin Biochem 2008;45:318-319.